Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder

PharmacoEconomics

Volumn 23, Issue 2, 2005, Pages 155-167

  Fernandez, José Luis ^a   Montgomery, Stuart ^b   Francois, Clément ^c  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c Lundbeck   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ABSENTEEISM; ADULT; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC EVALUATION; EXTENDED DRUG RELEASE; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAL SERVICE; MULTICENTER STUDY; OUTPATIENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSITIVITY ANALYSIS; SUSTAINED DRUG RELEASE;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; COST-BENEFIT ANALYSIS; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 16244418668     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200523020-00007     Document Type: Review

References (42)

1. Kind P, Sorensen J. Modelling the cost-effectiveness of the prophylactic use of SSRIs in the treatment of depression. Int Clin Psychopharmacol 1995; 10 Suppl. 1: 41-8
2. Freeman H, Arikian S, Lenox-Smith A. Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom. Pharmacoeconomics 2000; 18 Suppl. 2: 143-8
3. Lock J, Walsh M. Development and implementation of depression care along the health care continuum. J Nurs Care Qual 1999; 13 Suppl. 3: 13-22
4. Keller MB, Hirschfeld RMA, Demyttenaere K, et al. Optimizing outcomes in depression: focus on antidepressant compliance. Int Clin Psychopharmacol 2002; 17: 265-71
5. Frank L, Revicki DA, Sorensen SV, et al. The economics of selective serotonin reuptake inhibitors in depression: a critical review. CNS Drugs 2001; 15: 59-83
6. Hylan TR, Kotsanos JG, Anderson JS. Comparison of a decision analytical model with results from a naturalistic economic clinical trial: an application to evaluating alternative antidepressants. Am J Manag Care 1996; 2: 1211-23
7. Revicki D, Irwin D, Reblando J, et al. The accuracy of self-reported disability days. Med Care 1994; 32: 401-4
8. Sclar DA, Skaer TL, Robison LM, et al. Economic appraisal of antidepressant pharmacotherapy: critical review of the literature and future directions. Depress Anxiety 1998; 8 Suppl. 1: 121-7
9. Doyle JJ, Casciano J, Arikian S, et al. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. Value Health 2001 Jan-Feb; 4 (1): 16-31
10. Hemels ME, Kasper S, Walter E, et al. Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. Curr Med Res Opin 2004 Jun; 20 (6): 869-78
11. Hemels ME, Kasper S, Walter E, et al. Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression. Ann Pharmacother 2004 Jun; 38 (6): 954-60. Epub 2004 Apr 27. [published erratum appears in Ann Pharmacother 2004 Sep; 38 (9): 1545]
12. Hemels ME, Kasper S, Walter E, et al. Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression. Ann Pharmacother 2004 Jun; 38 (6): 954-60. Epub 2004 Apr 27. [published erratum appears in Ann Pharmacother 2004 Sep; 38 (9): 1545]
13. François C, Sintonen H, Toumi M. Introduction of escitalopram, a new SSRI. in Finland: comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of budgetary impact. J Med Econ 2002; 5: 91-107
14. François C, Aakhus A-M, Hansen K. A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor: comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine and venlafaxine for the treatment of depression in Norway. Eur J Health Econ 2003; 4: 12-9
15. Montgomery SA, Huusom AKT, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004; 50: 57-64
16. Rudolph RL, Fabre LF, Feighner JP, et al. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 1998; 59: 116-22
17. Khan A, Upton V, Rudolph RL, et al. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. J Clin Psychopharmacol 1996; 49: 997-1002
18. EuroQOL Group. EuroQOL: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208
19. McKenna SP, Doward LC, Kohlmann T, et al. International development of the quality of life in depression scale (QLDS). J Affect Disord 2001; 63: 189-99
20. Netten A, Rees T, Harrison G. Unit costs of health and social care 2001. Personal Social Services Research Unit, University of Kent at Canterbury, 2001
21. Raikou M, Briggs A, McGuire A. Centre-specific or average units costs in multi-centre studies? Some theory and simulation. Health Econ 2000; 9 Suppl. 3: 191-8
22. Drummond M, Pand F. Transferability of economic evaluation results. In: McGuire A, editor. Economic evaluation in health care. New York: OHE, 2001: 256-76
23. Knapp M, Ilson S. Economic aspects of depression and its treatment. Curr Opin Psychiatry 2002; 15 Suppl. I: 69-76
24. Hutubessy RC, van Tulder MW, Vondeling H, et al. Indirect costs of back pain in the Netherlands: a comparison of the human capital method with the friction cost method. Pain 1999; 80: 201-7
25. Brooks R. EuroQol: the current state of play with the EuroQOL Group. Health Policy 1996; 37: 53-72
26. Dolan P, Gudex C, Kind P, et al. A social tariff for EuroQol: results from a UK general population survey. Discussion Paper 138, Centre for Health Economics, The University of York, UK. 1995
27. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001; 20 (4): 461-94
28. Sapin C, Fantino B, Nowicki ML, et al. Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual Life Outcomes 2004 May 5; 2 (1): 20
29. Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med 1990; 113: 147-54
30. Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ 1998; 7: 723-40
31. Schulberg H, Block MR, Madonia MJ. Treating major depression in primary care practice: eight-month clinical outcomes. Arch Gen Psychiatry 1996; 53: 913-9
32. Katon W, Von Korff M, Lin E. Collaborative management to achieve treatment guidelines: impact on depression in primary care. JAMA 1995; 273: 1026-31
33. Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997; 6: 217-27
34. Bosch JL, Hunink MG. Comparison of the Health Utilities Index Mark 3 (HUI3) and the EuroQol EQ-5D in patients treated for intermittent claudication. Quai Life Res 2000; 9: 591-601
35. Tidermark J. Quality of life and femoral neck fractures. Acta Orthop Scand Suppl 2003; 74 (309): 1-42
36. Garry R, Clayton R, Hawe J. The effect of endometriosis and its radical laparoscopic excision on quality of life indicators. Br J Obstet Gynaecol 2000; 107: 44-54
37. Sugahara H, Akamine M, Kondo T, et al. Somatic symptoms most often associated with depression in an urban hospital medical setting in Japan. Psychiatry Res 2004 Apr 30; 126 (2): 151-8
38. Harlow S, Linet MS. Agreement between questionnaire data and medical records: the evidence of accuracy or recall. Am J Epidemiol 1989; 129: 233-48
39. Koopmanschap MA, Touw KC, Rutten FF. Analysis of costs and cost-effectiveness in multinational trials. Health Policy 2001 Nov; 58 (2): 175-86
40. Lecrubier Y. Prescribing patterns for depression and anxiety worldwide. J Clin Psychiatry 2001; 62 Suppl. 13: 31-6
41. Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on the primary care management of depression from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 1999; 60 Suppl. 7: 54-61
42. Laukkala T, Isometsa E, Hamalainen J, et al. Antidepressant treatment of depression in the Finnish general population. Am J Psychiatry 2001; 158: 2077-9